Toll Free: 1-888-928-9744

Cardiolynx AG - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cardiolynx AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cardiolynx AG - Product Pipeline Review - 2014', provides an overview of the Cardiolynx AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cardiolynx AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cardiolynx AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cardiolynx AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cardiolynx AG's pipeline products

Reasons to buy

- Evaluate Cardiolynx AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cardiolynx AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cardiolynx AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cardiolynx AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cardiolynx AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cardiolynx AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cardiolynx AG Snapshot 5
Cardiolynx AG Overview 5
Key Information 5
Key Facts 5
Cardiolynx AG - Research and Development Overview 6
Key Therapeutic Areas 6
Cardiolynx AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Cardiolynx AG - Pipeline Products Glance 12
Cardiolynx AG - Clinical Stage Pipeline Products 12
Phase 0 Products/Combination Treatment Modalities 12
Cardiolynx AG - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Cardiolynx AG - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Cardiolynx AG - Drug Profiles 16
CLC-1201 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Organic Nitrate For Angina Pectoris 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
(organic nitrate + cilostazol) ER 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CLC-1200 Series 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CLC-3000 Series 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
valsartan dinitrate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
valsartan mononitrate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Cilostazol Dinitrate 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Cilostazol Mononitrate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CLC-1000 Series 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CLC-3001 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CLC-1011 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cardiolynx AG - Pipeline Analysis 28
Cardiolynx AG - Pipeline Products by Target 28
Cardiolynx AG - Pipeline Products by Route of Administration 30
Cardiolynx AG - Pipeline Products by Molecule Type 31
Cardiolynx AG - Pipeline Products by Mechanism of Action 32
Cardiolynx AG - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36
List of Tables
Cardiolynx AG, Key Information 5
Cardiolynx AG, Key Facts 5
Cardiolynx AG - Pipeline by Indication, 2014 8
Cardiolynx AG - Pipeline by Stage of Development, 2014 9
Cardiolynx AG - Monotherapy Products in Pipeline, 2014 10
Cardiolynx AG - Combination Treatment Modalities in Pipeline, 2014 11
Cardiolynx AG - Phase 0, 2014 12
Cardiolynx AG - Preclinical, 2014 13
Cardiolynx AG - Discovery, 2014 14
Cardiolynx AG - Unknown, 2014 15
Cardiolynx AG - Pipeline by Target, 2014 29
Cardiolynx AG - Pipeline by Route of Administration, 2014 30
Cardiolynx AG - Pipeline by Molecule Type, 2014 31
Cardiolynx AG - Pipeline Products by Mechanism of Action, 2014 33 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify